Patients’ Right to Know Their Medication Act of 2025

Bill Summary: Patients’ Right to Know Their Medication Act of 2025 (H.R. 5133)

Overview

The Patients’ Right to Know Their Medication Act of 2025 is a legislative proposal to amend the Federal Food, Drug, and Cosmetic Act. Its primary purpose is to mandate the inclusion of standardized, easy-to-read printed (paper) medication information (PMI) with all prescription drugs dispensed in non-hospital settings.

The bill is driven by the finding that electronic-only labeling can be inaccessible to many patients and that standardized paper inserts can significantly reduce adverse drug events and associated healthcare costs.

Key Provisions

1. New Mandatory Labeling Requirements

The bill directs the Secretary of Health and Human Services (HHS) to establish regulations for printed patient medication information. Key requirements include:
* Format: Information must be provided in a standardized, printed paper format using plain language, specific minimum font sizes, and graphics or pictures where applicable.
* Tone: The content must be scientifically accurate and strictly non-promotional.
* Delivery: A printed copy must be physically included on or within the packaging of every prescription dispensed to a patient.

2. Required Content

The standardized PMI must include, at a minimum:
* The drug's established name and National Drug Code.
* Approved indications for use and general directions for proper use.
* Safety Data: Contraindications, warnings, precautions, and common or serious adverse reactions (with specific emphasis on children, elderly, and pregnant women).
* Patient Guidance: Steps to reduce side effects and instructions on when to contact a healthcare professional.
* Logistics: Storage requirements, proper disposal instructions, and a prohibition against sharing medications.
* Interactions: Clinically important interactions with other drugs, foods, or substances.
* Manufacturer Contact: The name of the manufacturer and a toll-free telephone number.
* Reporting: A current link to FDA Form 3500B for reporting adverse events.

3. Compliance and Enforcement

• Misbranding: The bill amends the Federal Food, Drug, and Cosmetic Act to classify any drug that fails to provide this required patient medication information as "misbranded." This allows the FDA to take enforcement action against manufacturers who do not comply.
• Timeline: The Secretary must issue final regulations regarding these requirements within one year of the Act's enactment.

Who is Affected?

• Drug Manufacturers: Will be responsible for developing, printing, and including the standardized PMI in their drug packaging as part of their application for drug approval.
• Patients: Will receive a consistent, easy-to-understand physical document with every prescription, regardless of their access to digital technology.
• Healthcare Providers/Pharmacies: Will distribute these mandated inserts as part of the prescription dispensing process.

Potential Impact

• Public Health: By improving patient understanding and adherence, the bill aims to reduce "adverse drug events" (harmful medication errors).
• Economic Impact: The bill cites findings that standardized PMI could reduce emergency room visits and hospital admissions related to medication errors, potentially saving between $14.6 billion and $26.2 billion annually.
• Accessibility: It ensures that patients without internet access or digital literacy are not excluded from critical safety information.